CBS - The 17th Left Main & Coronary Bifurcation Summit, CBS2025

CBS 2019

CBSMD教育中心

HOME
CBS 2019
At CBS

General Information

Left Main & Coronary Bifurcation Summit (CBS) was founded in 2006 as a think tank dedicated to the treatment of left main and coronary bifurcation lesions. CBS aims to improve cardiological care by refreshing fundamental researches, clinical trials, yearly published guidelines, emerged ideas and case-based discussion.

Association and Affiliations
- Organized by
  
  Nanjing Heart Center
  
  Asian Bifurcation Club (ABC)
  
  Nanjing First Hospital, Nanjing Medical University
- Co-organized by
  
  Chinese Society of Cardiology (CSC)
  
  Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
  
  American Society for Cardiovascular Angiography and Interventions (SCAI)
  
  Asian Heart Society (AHS)
Contact Us
- Registration Administration of Domestic Representatives
  
  Hongjuan Peng : +86-13913895477
  
  Haimei Xu +86-13914736846
  
  cbsnj@cbsmd.cn
- Registration Administration of Overseas Representatives
  
  Ling Lin : +86 (25) 52271398
  
  +86-13951884596
  
  cbs@cbsmd.cn
- Management of Challenging Cases
  
  Yingying Zhao :+86-13815408517
  
  sub@cbsmd.cn
Address

CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China

210006
FACULTY
FACULTY

General Chairman
Congress Chairman
Course Directors International Faculty Domestic Faculty Hong Kong and Taiwan Faculty Members of Academic Committee
Education Center

Education Center

• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)

• CBS Education Resource

• CBSMD Scientific Library
SCIENTIFIC LIBRARY

SCIENTIFIC LIBRARY

Research Paper

> Acute Coronary Syndrom

> ASCVD Prevention

> Bifurcation Stenting

> Cardio-Oncology

> Congestive Heart Failure

> DAPT Duration

> Drug Coated Balloon

> Fractional Flow Reserve

> IVUS Guidance

> Optical Coherence Tomography

> Pulmonary Hypertension

> Rotational Atherectomy

> Shear Stress

> Stenting Left Main

> Transcatheter Aortic Valve Replacement

> Percutaneous LAA Occlusion

> Mitral/Tricuspid Valvular Disease

> Other Relevant Articles

Recommended Paper

Management of Acute Myocardial Infarction During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)

HOME | SCIENTIFIC LIBRARY | DAPT Duration

DAPT Duration

Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting - A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trial 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study

Sort by hits |<< 1 2 3 4 5 6 7 ...>>|

JOURNAL：CBS2017 Article Link

向世界发出中国心声——TCT2017系列报道一

CBS2017

美国丹佛——当地时间10月29日上午11时00到11时30分， Peter Block医生在TCT（经导管心血管治疗学术会议）的举办地Colorado Convention Center， ACCEL办公室对远赴重洋，来自中国的DK Crush系列研究负责人陈绍良教授进行了一次深入的专访。此次访问紧密围绕DKCRUSH-V 对治疗冠脉左主干动脉真性远端分叉病变的双对吻挤压技术 (the double kissing crush techniques)与单支架技术(provisional side branch stenting)这一大规模多中心临床随机对照试验展开。

介入器械的日趋成熟并未彻底攻克冠脉分叉病变这一心血管重大疾病难点，不同的治疗策略亟需高信度、高水平的试验设计进行比较，并进一步接受全球临床的实战检验。为此，陈绍良团队历时十载，一直致力于此，持之以恒地探索治疗左主干分叉病变的可靠疗法，期待我国的创新可以为全球病患带去福音。

TCT2017重要日程预告

TCT2017作为冠脉左主干病变处理、生物可吸收支架、经导管瓣膜病治疗领域的顶尖专业盛会，将汇集12项最新揭晓临床试验（LBCTs）和16项首次报道研究（FRIs）结果在本次大会上揭晓。南京市第一医院陈绍良教授团队的DKCRUSH-V研究作为最值得关注的成果之一，将于当地时间10月30日11时40分（北京时间11月1日凌晨1点40分）在TCT2017主会场发布。南京市第一医院将分别于当地时间11月1日上午8时在主会场和10:00在冠脉分会场进行前后两次手术转播，分别演示经皮肺动脉去交感神经术（PADN）治疗原发性肺动脉高压、双对吻挤压术治疗左主干末端分叉病变技术，两场手术均由陈绍良教授担任主要术者。

联系我们| Top

Abstract

Recommended Article

向世界发出中国心声——TCT2017系列报道一